Seasoned Healthtech Executive Pia Shivdasani Joins Karoo Health as COO
ALBUQUERQUE, N.M., July 23, 2025 /PRNewswire/ — Karoo Health, a technology company enabling cardiac value-based care, today announced that it has named Pia Shivdasani as Chief Operating Officer. Shivdasani brings operational leadership and execution strategy to Karoo, having most recently served as Vice President at Boulder Care, leading clinical operations. Earlier in her career, she served at the strategic investment firm Echo Health Ventures, as well as on the payer side at Cambia Health Solutions.
Karoo Health supports the transformation to value-based cardiac care through the combination of dedicated wraparound care teams, high-performing network steerage, and AI-powered technology that enables real-time patient communication, seamless data sharing, and actionable insights for both clinical and payer partners.
'Pia's unique background as an operator at a high-growth startup, an investor at a well-known venture capital firm, and a payer executive brings a distinctly unique and highly valuable perspective to our leadership team,' said Karoo Health CEO and Cofounder Ian Koons. 'We are fortunate to have her on board as we continue to scale nationally.'
'Patients navigating cardiac care need consistent, coordinated support beyond the clinical visit,' said Shivdasani. 'I'm energized by building solutions that meet these gaps, and I believe the only way to improve outcomes and lower cost of care at scale in the cardiac vertical is through the combination of deeply integrated provider partnerships, tailored patient interactions, and technology that empowers care teams to deliver more connected, effective care.'
Earlier this year, Karoo Health announced a partnership agreement with Medicare Advantage insurer Zing Health to launch a value-based cardiac care program across Illinois, Indiana, Michigan, Mississippi, Ohio, and Tennessee. The combination of Karoo's 500-plus cardiology provider partners, AI technology, and innovative model of care, and Zing's best-in-class member experience, helps solve a critical unmet need for Americans with cardiovascular disease.
Through the end of this year and early into 2026, Karoo will be continuing its rapid growth by partnering with new payers in at least five new states.
About Karoo HealthHeart disease is currently the leading cause of death in the United States, with one person dying every 34 seconds due to cardiovascular illness. Deploying an exclusive mix of AI-powered technology and specialized care, grounded in value-based principles, Karoo Health enables cardiology provider networks, health plans, and at-risk entities to seamlessly transition to, and succeed in, cardiac value-based care and excel in outcomes-driven initiatives. For more information, visit the company at www.karoohealth.com or connect with them on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
a day ago
- New Straits Times
#SHOWBIZ: Justin Timberlake reveals battle with 'relentlessly debilitating' Lyme disease
NEW YORK CITY: Justin Timberlake has disclosed that he was diagnosed with Lyme disease, describing it as "relentlessly debilitating." The singer made the candid revelation in an Instagram post after the final show of his Forget Tomorrow tour in Turkey. The 44-year-old artiste said he had been silently dealing with health issues throughout the tour. "I've been battling some health issues and was diagnosed with Lyme disease. I'm sharing this to shed light on what I've been up against, and not for sympathy," he wrote. Lyme disease is a bacterial infection spread by tick bites that can cause symptoms such as nerve pain, extreme fatigue, and cognitive difficulties. Timberlake said the diagnosis explained the nerve pain and exhaustion he experienced while performing. Despite the challenges, the *NSYNC alum chose to continue with the tour. "The joy that performing brings me far outweighs the fleeting stress my body was feeling. I'm so glad I kept going," he said. Timberlake added that he chose to go public to avoid misunderstandings and to demonstrate his resilience. "I wanted to be transparent, so my struggles wouldn't be misinterpreted. I'm proud of my mental tenacity," he explained. The tour, which began in April 2024, spanned Europe, North America, and Asia. It received mixed reviews, with some critics noting underwhelming performances, which now make more sense in light of his health battle. Timberlake, who has sold over 88 million records and won ten Grammy Awards, is married to actress Jessica Biel, 42. They share two sons, Silas and Phineas. He joins other celebrities like Avril Lavigne and Bella Hadid who have also spoken out about their experiences with Lyme disease. The US public health agency, the Centers for Disease Control and Prevention, estimates that the illness affects nearly half a million Americans each year.
The Sun
2 days ago
- The Sun
Trump pressures 17 pharma CEOs to cut US drug prices
WASHINGTON: President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday. Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas. Trump sent the letters to the chief executives of Eli Lilly , Sanofi, Regeneron, Merck & Co , Johnson & Johnson, and AstraZeneca, among others, the White House said. 'Most proposals my Administration has received to 'resolve' this critical issue promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry,' Trump wrote in the letters, copies of which were posted on his Truth Social account. Shares of Pfizer, Eli Lilly and Gilead Sciences closed down about 2% each, while the NYSE Arca Pharmaceutical Index fell 3% on Thursday. Trump called on drugmakers to provide so-called most-favored-nation prices to every patient enrolled in the government Medicaid health program for low-income people, and to guarantee such pricing for new drugs. The policy is aimed at cutting U.S. prescription drug prices to the lowest possible price paid by members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. Trump also said companies must return excess overseas revenue from raising prices in other countries to offset lower prices in the U.S. to American patients and taxpayers through an agreement with the government. He is requiring drugmakers to stipulate they would not offer other developed nations better prices than what they offer the United States, and said his administration would provide ways to cut out middlemen and sell directly to patients, provided they do so at most-favored-nation prices. Trump gave companies until September 29 to respond with binding commitments to those terms. 'If you refuse to step up, we will deploy every tool in our arsenal to protect Americans from abusive drug pricing practices,' he warned. Analysts, lobbyists and drug pricing experts said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. 'I might expect them to try to determine if any of their current products might be made available via direct sales (one of the requests) at a lower price than currently available in the U.S.,' said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University. UBS analyst Trung Huynh said Trump's letters were a repeat of earlier demands and played down any likely industry impact, calling it 'just another shot in the dark.' Trump has already pushed for voluntary changes and some companies have pledged to build new U.S. manufacturing plants. U.S. patients pay by far the most for prescription medicines, often nearly three times more than in other developed nations. The country also invests heavily in pharmaceutical research and development. Drugmakers have said drastic price cuts would stifle innovation. Pharmaceutical companies including Pfizer, Novartis , AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Pfizer is working closely with the Trump Administration and Congress to improve access and affordability for American patients, said spokeswoman Amy Rose. 'Our discussions have been productive,' she said-REUTERS
The Star
2 days ago
- The Star
US securities regulator lays out sweeping plans to accommodate crypto
FILE PHOTO: Chairman of the Securities and Exchange Commission (SEC) Paul Atkins looks on during his swearing-in ceremony, at the White House in Washington, D.C., U.S., April 22, 2025. REUTERS/Kevin Lamarque/File photo (Reuters) -The head of the U.S. securities regulator unveiled sweeping plans to overhaul capital markets regulations on Thursday to accommodate cryptocurrencies and blockchain-based trading, in a major win for the digital asset industry, which has long pushed for tailored rules. Securities and Exchange Commission Chair Paul Atkins said in remarks that he has directed commission staff to craft guidelines to determine when a crypto token is a security as well as proposals for a wide range of disclosures and exemptions. Atkins also said he has asked SEC staff to work with firms looking to offer tokenized securities -- blockchain-based shares of stocks or funds. "This represents more than a regulatory shift — it is a generational opportunity," Atkins said in a speech before the America First Policy Institute, a think tank that was created to support President Donald Trump's policy agenda. If enacted, Atkins' proposals would represent a broad shift for U.S. securities regulation, potentially enabling crypto to become more enmeshed with traditional finance. Details of his plans for crypto come just a day after a cryptocurrency working group formed by Trump called on the SEC to create new rules specific to digital assets and outlined the administration's stances on market-defining crypto legislation. In a landmark report, the White House encouraged the SEC and the Commodity Futures Trading Commission to use their existing authorities to "immediately enable the trading of digital assets at the federal level." On the campaign trail last year, Trump courted crypto cash by pledging to be a "crypto president" and promote the adoption of digital assets. That is in stark contrast to former Democratic President Joe Biden's regulators, who, in a bid to protect Americans from fraud and money laundering, cracked down on the industry. The Biden administration's SEC sued exchanges Coinbase, Binance, and dozens more, alleging they were flouting U.S. laws. Trump's SEC has since dropped those cases. (Reporting by Hannah Lang in New York; Editing by Aurora Ellis)
